Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study

This Chinese study is testing whether adding targeted radiation therapy (SBRT) before immunotherapy and chemotherapy improves outcomes compared to immunotherapy and chemotherapy alone as a pre-surgery treatment for patients with resectable stage II-III non-small cell lung cancer (NSCLC). **You may be eligible if...** - You have confirmed non-small cell lung cancer, stage IIa to IIIa (or potentially resectable IIIb) - Your tumor has been evaluated as removable by a surgical team - You are between 18 and 75 years old - You have good performance status (ECOG 0-1) - Your blood counts and organ function meet study requirements **You may NOT be eligible if...** - You have an autoimmune disease (with some exceptions) - You need systemic corticosteroids at high doses - You have had prior chest radiotherapy - Your NSCLC has EGFR mutation or ALK fusion (different targeted treatments are available) - You have active hepatitis B or C, or HIV - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.